SS-31, also known as elamipretide, is an innovatively designed mitochondrial-targeted tetrapeptide that has transformed pre-clinical perspectives on bioenergetic protection. Unlike traditional antioxidants that broadly scavenge reactive oxygen species (ROS), SS-31 selectively localizes to the inner mitochondrial membrane (IMM) where it interacts with cardiolipin to stabilize mitochondrial ultrastructure and improve the efficiency of the electron transport chain. All content is provided strictly for research reference.
Background and Discovery
The development of SS-31 originated from the research of Dr. Hazel Szeto in the early 2000s. The challenge was identifying a way to target mitochondrial oxidative stress without interfering with essential signaling pathways. Standard antioxidants often fail because they do not reach the required concentration inside the mitochondria or they indiscriminately quench ROS that are necessary for normal cellular signaling [1].
SS-31 (elamipretide) was engineered as a cell-permeable peptide that enters the mitochondria independently of mitochondrial membrane potential—a vital feature since dysfunctional mitochondria often lose their potential, making them unreachable for many other targeted compounds [3].
Molecular Structure and Mechanism
SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2 (where Dmt stands for 2',6'-dimethyltyrosine). This specific alternating aromatic-cationic motif is what grants the peptide its unique pharmacological profile:
- D-Arginine (D-Arg): The D-enantiomer prevents enzymatic degradation by peptidases, significantly extending the terminal half-life in research settings [2].
- Dimethyltyrosine (Dmt): This modification increases the electron-scavenging capacity of the tyrosine residue, allowing it to quench reactive species at the site of production [1].
- Positive Charge: The net +3 charge at physiological pH facilitates strong electrostatic attraction to the highly anionic inner mitochondrial membrane [4].
Cardiolipin Interaction: The Key Target
The primary mechanism of elamipretide is its selective binding to cardiolipin (CL), a unique phospholipid found almost exclusively in the IMM [2]. Cardiolipin is essential for the stabilization of cristae curvature and the formation of respiration supercomplexes (the grouping of Complexes I, III, and IV).
When cardiolipin is damaged via peroxidation, it detaches from the respiratory chain, leading to electron leakage and further ROS production. SS-31 binds to CL, stabilizing the cytochrome c-cardiolipin complex and preventing cytochrome c from behaving as a peroxidase [2,3]. This stabilization maintains efficient electron transfer and inhibits the opening of the mitochondrial permeability transition pore (mPTP), thereby preventing apoptosis [1].
Evidence Table: Mitochondrial Research Domains
Research into SS-31 has spanned multiple physiological systems, primarily focusing on conditions of acute or chronic mitochondrial distress.
| Research Domain | Observed Effect | Maturity of Research |
|---|---|---|
| Cardiovascular | Reduced infarct size in ischemia models; improved cardiac output [3] | High (Preclinical) |
| Renal Function | Protected podocytes; reduced tubulointerstitial fibrosis in kidney models [1] | Moderate |
| Neurological | Attenuated neuroinflammation; improved motor recovery in spinal injury [4] | Emerging |
| Metabolic | Restoration of energy balance in adipocytes; improved insulin sensitivity | Moderate |
| Skeletal Muscle | Improved skeletal muscle force and ATP recovery in aged models | High |
Research Domains: Cardiovascular and Neurological
Cardiovascular Protection
In models of ischemia-reperfusion (IR) injury, administration of SS-31 has been reported to significantly re-energize mitochondria by increasing ATP production and decreasing oxidative stress [3]. By stabilizing the IMM, the peptide prevents the release of pro-apoptotic factors, which is often the primary cause of cell death following a cardiac event in laboratory studies.
Neurological Impact
Recent longitudinal studies have investigated elamipretide in neurodegenerative contexts. By targeting the mitochondria in neurons and astrocytes, research indicates an attenuation of microglial activation and a reduction in the inflammatory cascade associated with traumatic brain injury and certain mitochondrial myopathies [4].
Clinical Landscape and Limitations
While preclinical data overwhelmingly supports the mitochondrial protective effects of SS-31, human clinical trials have seen more variable results. Most notably, the MMPOWER-3 Phase 3 trial, which investigated elamipretide for primary mitochondrial myopathy (PMM), failed to meet its primary endpoints of improving exercise capacity (measured by a 6-minute walk test) or reducing fatigue [5].
These discrepancies highlight the complexity of mitochondrial diseases in humans compared to controlled animal models. Researchers continue to explore SS-31 for more targeted applications, such as Barth syndrome and age-related macular degeneration (AMD), where cardiolipin dysfunction is more uniform.
Where to Source for Research
SS-31 is available strictly for laboratory research and development purposes. It is not for human or veterinary use. When selecting a provider, researchers should prioritize transparency in analytical testing and purity verification.
The following suppliers are recognized for providing high-purity research materials:
- Short Chain Aminos – https://shortchainaminos.io
- BioPep – https://biopep.io/
- Catalyst Research – https://catalyst-research.net
- Apex Research Services – https://apexresearchservices.org
For more information on selecting reputable providers, see our guide on how to evaluate research peptide suppliers.
Frequently Asked Questions
What is the primary target of SS-31 in the mitochondria?
Research identifies the phospholipid cardiolipin (CL) as the primary target. SS-31 binds selectively to CL in the inner mitochondrial membrane, which stabilizes the structure of the respiratory supercomplexes and prevents cytochrome c from leaking out or behaving as a peroxidase. This stabilization is central to its bioenergetic effects.
Is SS-31 considered a systemic antioxidant?
No. While it has antioxidant properties through its Dmt residue, it is classified as a "mitochondria-targeted protective agent." Unlike systemic antioxidants that broadly neutralize ROS throughout the cell, SS-31 specifically targets the mitochondrial source of oxidative stress, thereby preserving essential physiological ROS signaling in other cellular compartments.
How does elamipretide differ from MOTS-c?
SS-31/Elamipretide is a synthetic tetrapeptide designed for structural stabilization of the mitochondrial membrane. In contrast, MOTS-c is a 16-amino acid peptide naturally encoded in the mitochondrial genome that acts as a metabolic hormone, primarily influencing glucose metabolism and systemic energy balance. Their mechanisms are complementary but distinct.
Does SS-31 require a mitochondrial membrane potential to function?
One of the most significant aspects of SS-31 in research is that its entry into the mitochondria is independent of the mitochondrial membrane potential. This allows the peptide to reach and treat "stressed" or dysfunctional mitochondria that have lost their charge, where other potential-dependent molecules would be excluded.
What are the main research applications for SS-31?
Current laboratory research focuses on conditions characterized by mitochondrial dysfunction, including ischemia-reperfusion injury, chronic kidney disease, metabolic disorders, and certain rare genetic conditions like Barth syndrome. It is utilized to study the restoration of ATP production and the reduction of pathological oxidative stress.
Works Cited
- Szeto HH. Mitochondria-targeted peptide for therapeutic use. Br J Pharmacol. 2014;171(8):2029-39. doi:10.1111/bph.12518. PMID: 24709403.
- Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Structural targets for SS-31 (elamipretide) in mitochondria. Soft Matter. 2014;10(9):1254-61. doi:10.1039/c3sm52454a. PMID: 24117165.
- Birk AV, Liu S, Soong Y, Mills W, Singh P, Szeto HH. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-61. PMID: 23813215.
- Chao de la Barca JM, et al. Interactions between elamipretide (SS-31) and mitochondrial proteins. Life Sci. 2020;256:117978. PMID: 32554501.
- Karaa A, et al. Elamipretide in patients with primary mitochondrial myopathy: a randomized, double-blind, placebo-controlled, crossover trial (MMPOWER-2). Neurology. 2020;95(8):e1011-e1022. PMID: 32554581.